Trump Faces New Lawsuit Over Migrants Sent to Salvadoran Prison
The Trump administration is facing a new legal challenge to its arrangement with El Salvador to send migrants — and potentially US citizens — to a mega-prison infamous for its dangerous and unsanitary conditions.
The case, filed in federal court in Washington, is the first to directly target the State Department's agreement to pay millions of dollars to house people arrested in the United States in El Salvador's prison system, including the Centro de Confinamiento del Terrorismo, known as CECOT.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News24
17 minutes ago
- News24
Salvadoran at the heart of row over Trump's deportation policies arrested on return to the US
The Salvadoran migrant at the heart of a row over President Donald Trump's hardline deportation policies was returned to the United States on Friday and arrested on human smuggling charges. Kilmar Armando Abrego Garcia was brought back to the United States from El Salvador and charged with trafficking undocumented migrants, Attorney General Pam Bondi said. "Abrego Garcia has landed in the United States to face justice," Bondi said at a press conference. The US Supreme Court had ordered the Trump administration to "facilitate" the return of Abrego Garcia after he was mistakenly deported in March to a notorious maximum security prison in El Salvador. But Bondi insisted to reporters that his return to the United States resulted from an arrest warrant presented to Salvadoran authorities. "We're grateful to (Salvadoran) President (Nayib) Bukele for agreeing to return him to our country to face these very serious charges," she said. In a post on X, Bukele said "we work with the Trump administration, and if they request the return of a gang member to face charges, of course we wouldn't refuse." Trump, in remarks to reporters Friday, described Abrego Garcia as a "pretty bad guy" and said he "should've never had to be returned." White House deputy press secretary Abigail Jackson said Abrego Garcia's return "has nothing to do with his original deportation." "There was no mistake," Jackson said on X. "He's returning because a new investigation has revealed crimes SO HEINOUS, committed in the US, that only the American Justice System could hold him fully accountable." Abrego Garcia, 29, was living in the eastern state of Maryland until he became one of more than 200 people sent to a prison in El Salvador as part of Trump's crackdown on undocumented migrants. Most of the migrants who were summarily deported were alleged members of the Venezuelan gang Tren de Aragua, which the Trump administration has declared a foreign terrorist organisation. 'Administrative error' Justice Department lawyers later admitted that Abrego Garcia - who is married to a US citizen - was wrongly deported due to an "administrative error." Abrego Garcia had been living in the United States under protected legal status since 2019, when a judge ruled he should not be deported because he could be harmed in his home country. Simon Sandoval-Moshenberg, one of Abrego Garcia's attorneys, said the government had returned him to the United States "not to correct their error but to prosecute him." "Due process means the chance to defend yourself before you're punished, not after," Sandoval-Moshenberg said. "This is an abuse of power, not justice." Bondi alleged that Abrego Garcia had "played a significant role in an alien smuggling ring" and was a smuggler of "children and women" as well as members of the Salvadoran gang MS-13. She said Abrego Garcia, who was indicted by a grand jury in Tennessee, would be returned to El Salvador upon completion of any prison sentence. Democratic Senator Chris Van Hollen visited Abrego Garcia in April in El Salvador and welcomed his return to the United States. "For months the Trump Administration flouted the Supreme Court and our Constitution," the senator from Maryland said in a statement. "Today, they appear to have finally relented to our demands for compliance with court orders and with the due process rights afforded to everyone in the United States," he said. "The Administration will now have to make its case in the court of law, as it should have all along." According to the indictment, Abrego Garcia was involved in smuggling undocumented migrants from Guatemala, El Salvador, Honduras and other countries into the United States between 2016 and earlier this year.
Health Line
23 minutes ago
- Health Line
Ask the Expert: Should I have Biomarker Testing – and Would it Help?
Biomarker testing in colorectal cancer can help assess inherited risk and identify characteristics that may influence the disease's growth, spread, and response to treatment. Colorectal cancer (CRC) starts in the colon or rectum of the large intestine. Your doctor may refer to it as 'colon cancer' or 'rectal cancer,' depending on where the cancer develops first, but both of these diagnoses are included under the banner of CRC. CRC is treatable, and biomarker testing is a part of precision medicine in your comprehensive treatment plan. Biomarker testing in CRC can help detect cancer in its earliest, most treatable stages. It can also provide important details about cancer after a diagnosis that influence treatment and outcomes. Dr. Smitha Krishnamurthi, a gastrointestinal oncology specialist with the Cleveland Clinic, talks with Healthline about biomarker testing and who it's recommended for. What is biomarker testing? Biomarker testing refers to testing of the colorectal cancer to find out if there are certain changes in the cancer's genes and proteins that could impact prognosis [outlook] and treatment. What are the most common biomarkers, and what do they show? Biomarkers in CRC measure a variety of different biological processes and states. Each biomarker provides important details about the cancer's growth, spread, or treatment response. DNA mismatch repair Hospital pathology labs now commonly test all initial biopsies or surgical specimens of colorectal cancer for the presence of DNA mismatch repair proteins. This is done via immunohistochemistry (IHC) staining of the slides to look for [the] expression of four mismatch repair proteins: MLH1, PMS2, MSH2, and MSH6. If one or two of these proteins are missing, then the cancer has deficient DNA mismatch repair. Microsatellite instability (MSI) This is a polymerase chain reaction (PCR) or next-generation sequencing (NGS) test [that looks] for abnormalities in microsatellite regions of the cancer DNA. The test can be done on a tumor specimen or blood (liquid biopsy). Microsatellites are short, repeated sequences of DNA. If the cancer has [atypical] DNA mismatch repair, errors will appear in microsatellite regions of DNA in the form of missing bases or extra bases added to the DNA sequence. RAS gene mutations (mutations in KRAS and NRAS genes) This testing can be performed by PCR or NGS testing of the tumor or NGS testing of blood (liquid biopsy). RAS is a very important oncogene, meaning that it is a gene that, when mutated, drives cancer cell proliferation and survival. Mutations in RAS genes are found in up to 50% of colorectal cancers. BRAF V600E gene mutation This testing can be performed by PCR or NGS testing of the tumor or NGS testing of blood (liquid biopsy). The BRAF V600E protein can also be detected by IHC. BRAF is another oncogene, so when it is mutated, it leads to cancer cell proliferation and survival. BRAF V600E mutations occur in about 8% to 10% of colorectal cancers and are more common in right-sided cancers. HER2 protein overexpression by IHC or gene amplification by NGS HER2 is another oncogene — gene amplification leads to [the] overexpression of the HER2 protein. Overexpression of HER2 leads to increased signaling via the epidermal growth factor receptor pathway, leading to cancer cell proliferation and survival. PIK3CA PIK3CA is another oncogene. Mutations in PIK3CA and a related gene, PIK3R1, lead to cancer cell proliferation and survival. Mutations in PIK3CA and PIK3R1 are typically found via NGS. PTEN PTEN is a tumor suppressor gene, [which typically] suppresses cancer growth. When the PTEN gene is mutated, the protein is not expressed, and that leads to [the] proliferation of cancer. PTEN gene mutations are typically found via NGS. Who should have biomarker testing done? All patients with colorectal cancer should have testing of their cancer for DNA mismatch repair (or microsatellite instability) soon after diagnosis. This is important for patients with cancers of all stages. Patients with early stage colorectal cancer should have testing of their cancers for mutations in PIK3CA, PTEN, and PIK3R1 by the time they finish adjuvant treatment or after surgery if [they're] not having adjuvant treatment. Patients with metastatic colorectal cancer should have next-generation sequencing of the cancer soon after diagnosis, as the results may impact the initial systemic treatment. The NGS results are also useful for identifying clinical trial eligibility. Comorbidities will not affect the results of these biomarkers, so they should not affect the timing and decision making about ordering these tests. How does biomarker testing help the treatment and outcome of a diagnosis? Biomarkers can impact your treatment choices and outcomes. They can help doctors decide which medications will be the most effective, identify inherited features in cancer, and determine if adjuvant or additional therapies would improve outcomes. Immunotherapy responsiveness It is critical to know if a cancer has deficient DNA mismatch repair (dMMR) or high microsatellite instability (MSI-H) because these cancers can respond dramatically to immunotherapy in the early stage and metastatic settings. For example, patients with rectal cancer that is dMMR or MSI-H may have a complete clinical response with immunotherapy and may be able to avoid radiation and surgery. Thus, this testing needs to be done early, before treatment starts. Identifying Lynch syndrome Another important reason for testing for dMMR or MSI-H is to identify cancers caused by Lynch syndrome. Lynch syndrome is the most common type of inherited colorectal cancer and is caused by germline mutations in the genes that code for the DNA mismatch repair proteins or in another related gene called EPCAM. Most cancers with deficient mismatch repair or MSI-H are not caused by Lynch syndrome and occur sporadically. We don't want to miss patients with Lynch syndrome, however, because they can benefit from counseling about [the] prevention of Lynch syndrome-related cancers such as uterine cancer, ovarian cancer, and gastric cancer, in addition to colorectal cancer. When a patient is diagnosed with Lynch syndrome, family members can then be tested to see if they have Lynch syndrome. Recommendations for cancer screening at early stages are made for individuals with Lynch syndrome, and early screening can be lifesaving. Identifying treatment resistance Mutations in KRAS and NRAS make cancers resistant to anti-epidermal growth factor receptor therapy. Cancers with KRAS G12C mutations can be treated with a regimen that targets this mutation (adagrasib plus cetuximab or sotorasib plus panitumumab). There are also many clinical trials now studying RAS gene inhibitors in patients with metastatic colorectal cancer that have been previously treated. Cancers with BRAF V600E tend to be aggressive and less sensitive to chemotherapy. There is a Food and Drug Administration (FDA)-approved regimen targeting BRAF V600E (encorafenib plus cetuximab) in metastatic colorectal cancer that improves survival when added to first-line FOLFOX chemotherapy. It also improves survival as a second-line treatment after chemotherapy. Greater response to targeted and adjuvant therapy Metastatic colorectal cancers that demonstrate [the] overexpression or gene amplification of HER2 can be treated with a targeted regimen of tucatinib plus trastuzumab after initial chemotherapy. Another targeted treatment available for metastatic colorectal cancers that overexpress HER2 by IHC is trastuzumab deruxtecan. Patients with early stage colorectal cancer with mutations in the PIK3CA, PIK3R1, or PTEN genes should be treated with aspirin 160 milligrams daily for 3 years after adjuvant therapy or after surgery if [they're] not having adjuvant therapy. The ALASCCA trial, presented at ASCO GI [American Society of Clinical Oncology – Gastrointestinal Cancer] in 2025, compared a placebo to aspirin in this patient population and found that aspirin significantly lowered the rate of cancer recurrence at 3 years. This is rather new data. Oncologists are starting to order NGS testing for patients with early stage cancers in order to obtain this biomarker information. What should you ask your doctor? It's always OK to ask your doctor about biomarker testing and what it means for you. Important questions to consider include: Is my cancer dMMR/MSI-H? Am I a candidate for immunotherapy? Patients with early stage colorectal cancer should ask if aspirin therapy will be recommended based on biomarker testing. Patients with metastatic colorectal cancer should ask for the results of RAS/BRAF/HER2 testing and overall NGS testing results.
Yahoo
31 minutes ago
- Yahoo
Clarksville police investigating shooting that left 1 person injured
CLARKSVILE, Tenn. (WKRN) — The Clarksville Police Department is investigating a shooting that left one person injured. Clarksville police were called to a convenience store in the 900 block of Crossland Avenue at about 9:35 p.m. Friday after getting a 911 call about a shooting that had already happened in the store's parking lot. READ MORE | Latest headlines from Clarksville and Montgomery County Arriving officers found one victim with a non-life-threatening graze wound. Anyone with surveillance cameras in the area has been asked to review their footage. If you see anything suspicious, you're advised to call 911 immediately. No further details were immediately released as the Clarksville Police Department said this is an active, ongoing investigation. 📲 Download the News 2 app to stay updated on the go.📧 Sign up for WKRN email alerts to have breaking news sent to your inbox.💻 for Nashville, TN and all of Middle Tennessee. This is a developing story. WKRN News 2 will continue to update this article as new information becomes available. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
